A company that’s hoping to be the first to commercialize a blood test that can diagnose the cause of stroke has closed $800,000 of an anticipated $1.1 million series B round of investment. Cincinnati-area-based IschemiaCare expects to close on the full $1.1 million by the end of the year. The funding will enable the company to reach a couple key milestones, CEO Jeff June said. The company will use the investment to establish a certified CLIA lab and test up to 500 samples with the goal of showing the stroke test’s accuracy.
